GlassScriptPhysician profile
Angela R Brown
NPI 1497183560
$9,790.70
in general payments reported to CMS, 2019-2025
34 companies · $2,850 in 2025
The $2,850 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,488 · 2022: $1,863 · 2023: $1,460 · 2024: $2,129 · 2025: $2,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,439.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,457.96 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,123.99 | 2021-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $1,041.81 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $928.74 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $613.77 | 2021-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $533.24 | 2021-2025 | Dupixent |
| Kowa Pharmaceuticals America, INC. | $422.08 | 2022-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $364.80 | 2021-2023 | Xarelto |
| Alkermes, INC. | $359.10 | 2021-2022 | |
| Abbvie INC. | $327.94 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $246.23 | 2021 | |
| Xeris Pharmaceuticals, INC. | $221.56 | 2024-2025 | Recorlev |
| Incyte Corporation | $201.49 | 2022 | |
| Astellas Pharma US INC | $197.50 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.01 | 2021-2025 | Combivent Respimat, Spiriva Respimat, Stiolto Respimat |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $142.84 | 2022 | |
| Stryker Corporation | $133.08 | 2025 | Mako |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2024 | |
| Neurocrine Biosciences, INC. | $125.00 | 2021 | |
| Pfizer INC. | $125.00 | 2025 | |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
| Amgen INC. | $124.99 | 2024 | Repatha |
| Madrigal Pharmaceuticals | $123.86 | 2024 | Rezdiffra |
| Dexcom, INC. | $116.67 | 2023 | Dexcom G7 Gss (161) |
| Boston Scientific Corporation | $103.08 | 2022-2023 | Spectra Wavewriter |
| Novartis Pharmaceuticals Corporation | $70.44 | 2021-2022 | |
| Exact Sciences Corporation | $28.91 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $23.91 | 2024 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $19.65 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.06 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.56 | 2025 | Caplyta |
| Scilex Pharmaceuticals INC. | $17.37 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $15.06 | 2023 | Acuvue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.